Follistatin-344 'Dosing': Why No Real Protocol Exists
Follistatin-344 is the 344-amino-acid isoform of follistatin, an activin-binding protein studied in laboratory and animal research as a myostatin pathway antagonist. It is sold online as an injectable research peptide, not as an approved drug, and it should not be confused with Follistatin-288 (a different splice variant with distinct tissue-binding behavior) or with engineered constructs like Follistatin-288-Fc or ACE-083, which are separate molecules built specifically to overcome the problems described below. See our Follistatin-344 vs 315 comparison for how the isoforms differ.
What are vendors actually claiming?
Search any research-chemical vendor site and you will find dosing tables: reconstitution instructions, "cycle lengths" of 4 to 8 weeks, daily microgram ranges, and injection-site rotation advice. These read like clinical protocols. They are not. No peer-reviewed human trial has published a dose-response curve, a maximum tolerated dose, or a pharmacokinetic profile for injected Follistatin-344 in people. The numbers circulating in vendor literature and forum posts have no traceable origin in the cited evidence base; they should be treated as unsourced practice, not as data.
This matters because dosing decisions in real medicine come from measured exposure and response, not from consensus among sellers. When a molecule has no human PK study, "dosing" is a placeholder word for a guess.
Why is the native protein hard to dose in the first place?
Follistatin has a short functional half-life in circulation, and this is a big part of why drug developers have not pursued the native 344-residue protein as a standalone injectable therapeutic. Researchers working on activin-based heart failure and fibrosis models have had to account for follistatin's endoplasmic reticulum stress interactions and rapid clearance dynamics (Effects of the Activin A-Follistatin System on Myocardial Cell Apoptosis, 2017). More directly, a 2018 pharmacology paper set out explicitly to re-engineer recombinant human follistatin because its native pharmacokinetic characteristics were inadequate for therapeutic use, modifying the protein to extend its exposure profile (Protein Engineering on Human Recombinant Follistatin, 2018). That paper's entire premise is that the unmodified protein does not stay active in the body long enough to be useful at a practical dosing frequency.
Separately, teams building Follistatin-288-Fc fusion constructs did so specifically to achieve localized, sustained muscle growth signaling that the native molecule could not deliver on its own (Follistatin-288-Fc Fusion Protein Promotes Localized Growth of Skeletal Muscle, 2019), and the ACE-083 ligand-trap program took a similar engineering route for neuromuscular disease models (ACE-083 ligand trap induces localized hypertrophy, 2019). In other words, the scientific groups closest to this biology chose to build entirely different molecules rather than dose native Follistatin-344 in humans. That choice is itself evidence about the dosing problem.
Could a short half-life explain why some users report needing multiple daily injections?
This is plausible pharmacology reasoning, not a confirmed human finding. A protein with rapid clearance would, in principle, require more frequent dosing to maintain any measurable effect, which may explain why some vendor protocols recommend multiple daily injections. But no published human data confirms an actual clearance rate, an effective trough concentration, or whether repeated dosing in people produces the muscle changes seen in animal models. The mechanistic logic is sound; the human confirmation is missing. That gap is worth stating plainly rather than letting a plausible mechanism stand in for evidence.
What does the animal evidence actually show, and does it transfer to a dosing schedule?
Animal and cell studies give a sense of biological plausibility, not a human protocol. A murine radiation fibrosis study found follistatin reduced fibrotic remodeling in irradiated tissue (Follistatin attenuates radiation-induced fibrosis, 2017), and C2C12 myotube experiments have shown follistatin treatment altering calcium-handling protein expression relevant to muscle contraction (Follistatin treatment suppresses SERCA1b levels, 2017). A separate in vivo study distinguished how the follistatin N-terminus differentially affects muscle size versus fat mass (Follistatin N terminus differentially regulates muscle size and fat, 2017). These are legitimate, interesting findings. None of them used the specific commercial Follistatin-344 product sold to consumers, none used a human subject, and none establishes a dose that scales from a mouse or a cell culture well to a person. For a fuller look at what the muscle-growth literature does and does not show, see our Follistatin-344 muscle evidence review.
Should someone use a vendor's suggested protocol?
Site judgment, not a guideline recommendation: no. A dosing schedule copied from a vendor page carries the same evidentiary weight as an unverified forum post, because that is usually its actual source. There is no regulatory body reviewing these numbers for safety margins, no established maximum dose, and no published adverse-event monitoring in humans to compare against. Compounded or vendor-sold Follistatin-344 is not FDA-approved for any indication, and it is not on the FDA's 503A bulk drug substances list (FDA 503A bulk substances list). Anyone considering use should read the Follistatin-344 side effects and risks page and the FDA Peptide Status Tracker for current regulatory status, and understand that "protocol" language in this space describes a habit among sellers and users, not a studied intervention.
A framework for reading any Follistatin-344 dosing claim
Use this checklist before treating a stated dose, frequency, or cycle length as meaningful:
| Question to ask | What a real answer requires | What vendor claims typically offer |
|---|---|---|
| Is there a published human PK study for this exact molecule? | A peer-reviewed trial measuring plasma concentration over time in people | None exists |
| Was the effect shown in the same species making the claim? | Human trial data, not mouse or myotube data | Usually animal or cell-culture only |
| Was the tested molecule identical to what is sold? | Same isoform, same modification status (native vs. Fc-fusion) | Often a different construct (e.g., Fc-fusion, ligand trap) |
| Does the source explain why the native protein needed re-engineering? | Acknowledgment of half-life and clearance limitations | Rarely mentioned |
| Is there a stated maximum tolerated dose or safety ceiling? | Dose-escalation study data | Never present |
If a claim fails more than one of these, treat the "dose" as a number someone made up, not a therapeutic parameter.
What is established, what is plausible, and what is not established
Established: native follistatin has pharmacokinetic limitations serious enough that drug developers engineered fusion proteins specifically to address them (Protein Engineering on Human Recombinant Follistatin, 2018; Follistatin-288-Fc Fusion Protein, 2019). Plausible but unproven: that a short half-life explains real-world user reports of frequent injection schedules, and that animal-model muscle or fibrosis effects would replicate in humans at any dose. Not established: any specific safe or effective human dose, frequency, or cycle length for Follistatin-344, and any claim that vendor protocols reflect studied pharmacology rather than marketing convention.
None of this constitutes dosing advice, and nothing here should be read as a recommendation to use an unapproved research compound. If you are experiencing symptoms you believe are related to a peptide product, seek care from a qualified clinician or urgent care rather than adjusting a self-sourced protocol. For background on the molecule itself, start with what Follistatin-344 is and the myostatin mechanism overview.